|Reviewer||Employment||Research Grant||Other Research Support||Speakers Bureau/Honoraria||Expert Witness||Ownership Interest||Consultant/Advisory Board||Other|
|Cristina Basso||University of Padua Medical School (Italy)||None||None||None||None||None||None||None|
|Susan P. Etheridge||University of Utah||None||None||None||None||None||SADS board∗||None|
|Timothy F. Feltes||Nationwide Children’s Hospital/Ohio State University||None||None||None||None||None||None||None|
|Samuel O. Jones IV||US Air Force, USUHS||None||None||None||None||None||None||None|
|Brian Olshansky||Executive Health Resources†||None||None||None||None||None||Biocontrol∗; Boston Scientific∗; Boehringer Ingelheim∗; Daiichi Sankyo∗|
|Satish Raj||University of Calgary (Canada)||None||None||None||None||None||None||None|
This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10,000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.